BR112015026512A2 - composto acetamida heterocíclico - Google Patents

composto acetamida heterocíclico

Info

Publication number
BR112015026512A2
BR112015026512A2 BR112015026512A BR112015026512A BR112015026512A2 BR 112015026512 A2 BR112015026512 A2 BR 112015026512A2 BR 112015026512 A BR112015026512 A BR 112015026512A BR 112015026512 A BR112015026512 A BR 112015026512A BR 112015026512 A2 BR112015026512 A2 BR 112015026512A2
Authority
BR
Brazil
Prior art keywords
disease
compound
positive allosteric
dopamine
receptor
Prior art date
Application number
BR112015026512A
Other languages
English (en)
Other versions
BR112015026512B1 (pt
Inventor
Moritomo Hiroyuki
Ohmiya Makoto
Shiraki Ryota
Kawakami Shimpei
Tobe Takahiko
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BR112015026512A2 publication Critical patent/BR112015026512A2/pt
Publication of BR112015026512B1 publication Critical patent/BR112015026512B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)

Abstract

resumo “composto acetamida heterocíclico” [problema]um composto que é útil como um modulador alostérico positivo do receptor d1 de dopamina (d1 pam) é fornecido. [meios para a solução]os presentes inventores estudaram um composto que tem uma atividade moduladora alostérica positiva do receptor d1 de dopamina e é útil como um ingrediente ativo de uma composição farmacêutica para prevenir e/ou tratar disfunção cognitiva, sintomas negativos de esquizofrenia, doença de parkinson, doença de alzheimer, doença de huntington, toxicodependências, ou semelhantes e, assim, descobriram que um composto acetamida heterocíclico tem uma atividade moduladora alostérica positiva do receptor d1 de dopamina, desse modo completando a presente invenção. o composto acetamida heterocíclico da presente invenção tem uma atividade moduladora alostérica positiva do receptor d1 de dopamina e pode ser usado como um agente para prevenir e/ou tratar disfunção cognitiva, sintomas negativos de esquizofrenia, doença de parkinson, doença de alzheimer, doença de huntington, toxicodependências, ou semelhantes.
BR112015026512-0A 2013-04-18 2014-04-18 Composto de acetamida heterocíclico ou um sal deste, composição farmacêutica compreendendo dito composto e uso do mesmo BR112015026512B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013087151 2013-04-18
JP2013-087151 2013-04-18
PCT/JP2014/061007 WO2014171528A1 (ja) 2013-04-18 2014-04-18 ヘテロ環酢酸アミド化合物

Publications (2)

Publication Number Publication Date
BR112015026512A2 true BR112015026512A2 (pt) 2017-07-25
BR112015026512B1 BR112015026512B1 (pt) 2023-03-14

Family

ID=51729480

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015026512-0A BR112015026512B1 (pt) 2013-04-18 2014-04-18 Composto de acetamida heterocíclico ou um sal deste, composição farmacêutica compreendendo dito composto e uso do mesmo

Country Status (33)

Country Link
US (2) US8937087B2 (pt)
EP (1) EP2987793B1 (pt)
JP (1) JP6252582B2 (pt)
KR (1) KR102193247B1 (pt)
CN (1) CN105121435B (pt)
AR (1) AR095883A1 (pt)
AU (1) AU2014254768B2 (pt)
BR (1) BR112015026512B1 (pt)
CA (1) CA2909783C (pt)
CY (1) CY1119754T1 (pt)
DK (1) DK2987793T3 (pt)
EA (1) EA028968B1 (pt)
ES (1) ES2651866T3 (pt)
HK (1) HK1214248A1 (pt)
HR (1) HRP20171786T1 (pt)
HU (1) HUE036054T2 (pt)
IL (1) IL241962B (pt)
LT (1) LT2987793T (pt)
ME (1) ME02891B (pt)
MX (1) MX2015014646A (pt)
MY (1) MY175971A (pt)
NO (1) NO2987793T3 (pt)
NZ (1) NZ713118A (pt)
PH (1) PH12015502341B1 (pt)
PL (1) PL2987793T3 (pt)
PT (1) PT2987793T (pt)
RS (1) RS56865B1 (pt)
SA (1) SA515370015B1 (pt)
SG (1) SG11201508448RA (pt)
SI (1) SI2987793T1 (pt)
TW (1) TWI625329B (pt)
UA (1) UA116243C2 (pt)
WO (1) WO2014171528A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR105025A1 (es) * 2015-06-19 2017-08-30 Astellas Pharma Inc Compuesto de imidazodiazepina
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
US20220033418A1 (en) 2018-09-13 2022-02-03 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
CN110590576A (zh) * 2019-08-15 2019-12-20 安徽金禾实业股份有限公司 一种4-多氟代甲氧基邻苯二胺的制备方法
CN114380709B (zh) * 2021-12-31 2023-07-21 西北农林科技大学 4-氯-2-酰氨基酚的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674524B1 (fr) * 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
WO2000059905A1 (en) * 1999-04-02 2000-10-12 Neurogen Corporation ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS
AUPQ309399A0 (en) 1999-09-28 1999-10-21 Fujisawa Pharmaceutical Co., Ltd. Benzothiazoline derivatives
EP1434765B1 (en) 2001-09-14 2009-12-02 High Point Pharmaceuticals, LLC Substituted piperidines with selective binding to histamine h3-receptor
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
CA2478183C (en) 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
ATE394400T1 (de) 2003-03-14 2008-05-15 Merck & Co Inc Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
CA2554774A1 (en) * 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. Novel heterocyclic compound
WO2005118561A1 (en) 2004-05-27 2005-12-15 Ucb, S.A. Benzoxazolone derivatives, processes for preparing them and their uses
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
US7576106B2 (en) 2005-10-11 2009-08-18 Chemocentryx, Inc. Piperidine derivatives and methods of use
CL2007002097A1 (es) 2006-07-20 2008-01-18 Smithkline Beecham Corp Compuestos derivados de pirrolidina o morfolina antagonistas de urotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar insuficiencia cardiaca congestiva, insuficiencia cardiaca isquemica, angina, isquemia del miocardio, vejiga hiperactiva, asma y/o copd, entre otras.
US7786157B2 (en) 2007-03-16 2010-08-31 Chemocentryx, Inc. OXO-imidazolidines as modulators of chemokine receptors
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
GB0713686D0 (en) * 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2

Also Published As

Publication number Publication date
AU2014254768A1 (en) 2015-11-05
ME02891B (me) 2018-04-20
HUE036054T2 (hu) 2018-06-28
ES2651866T3 (es) 2018-01-30
WO2014171528A1 (ja) 2014-10-23
UA116243C2 (uk) 2018-02-26
CN105121435B (zh) 2017-09-29
MX2015014646A (es) 2016-03-01
EA028968B1 (ru) 2018-01-31
JPWO2014171528A1 (ja) 2017-02-23
US20150045402A1 (en) 2015-02-12
TWI625329B (zh) 2018-06-01
BR112015026512B1 (pt) 2023-03-14
SG11201508448RA (en) 2015-11-27
CY1119754T1 (el) 2018-06-27
KR102193247B1 (ko) 2020-12-22
SI2987793T1 (en) 2018-02-28
US8937087B2 (en) 2015-01-20
RS56865B1 (sr) 2018-04-30
PH12015502341A1 (en) 2016-02-22
CN105121435A (zh) 2015-12-02
PT2987793T (pt) 2017-12-19
IL241962B (en) 2019-03-31
US20140315963A1 (en) 2014-10-23
PL2987793T3 (pl) 2018-05-30
JP6252582B2 (ja) 2017-12-27
NZ713118A (en) 2019-03-29
NO2987793T3 (pt) 2018-03-24
SA515370015B1 (ar) 2017-11-27
HRP20171786T1 (hr) 2018-02-23
AU2014254768B2 (en) 2017-10-05
CA2909783C (en) 2021-02-02
MY175971A (en) 2020-07-19
EP2987793B1 (en) 2017-10-25
PH12015502341B1 (en) 2016-02-22
DK2987793T3 (en) 2017-12-18
EP2987793A4 (en) 2016-09-07
AR095883A1 (es) 2015-11-18
CA2909783A1 (en) 2014-10-23
LT2987793T (lt) 2018-01-10
EP2987793A1 (en) 2016-02-24
KR20150143468A (ko) 2015-12-23
TW201518298A (zh) 2015-05-16
US9708307B2 (en) 2017-07-18
HK1214248A1 (zh) 2016-07-22
EA201591988A1 (ru) 2016-02-29

Similar Documents

Publication Publication Date Title
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
BR112015026512A2 (pt) composto acetamida heterocíclico
BR112016024472A2 (pt) composto, medicamento, métodos para modulação alostérica positiva e para profilaxia ou tratamento de doenças, e, uso de um composto
PE20151655A1 (es) Aglomerados respirables de particulas de vehiculo porosas y farmaco micronizado
BR112015023658A2 (pt) formulação de vitamina d de liberação modificada, estabilizada e método de administração desta
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112014026493A2 (pt) derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta
BR112015020963A2 (pt) derivado de 2-acilaminotiazola ou sal do mesmo
BR112016006444A2 (pt) derivado de triazolopirazina e uso do mesmo
BR112016027435A2 (pt) formulação inovadora de meloxicam
BR112021022378A2 (pt) Derivado de tetraidroisoquinolina substituído como um modulador alostérico d1 positivo
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
CL2011002650A1 (es) Composicion que comprende n-(4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il)-2-metilpiridin-5-carboxamida y l-dopa; uso del compuesto para el tratamiento de un trastorno del movimiento secundario de la terapia con l-dopa; uso del compuesto y l-dopa y/o para el tratamiento y/o profilaxis de la enfermedad de parkinson.
BR112014016472A8 (pt) formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo
BR112016017897A8 (pt) uso de composto de carboxamida heterocíclica de diamino no tratamento de câncer relacionado ao axl, composição farmacêutica e combinação
BR112016028270A2 (pt) derivado de 2-acilaminotiazol ou sal do mesmo
CL2015002817A1 (es) Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca).
BR112017006690A2 (pt) composto derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo
BR112015023694A2 (pt) entrega craniana de fármacos
EA201890120A1 (ru) Многофазные композиции
BR112016008654B8 (pt) Compostos bicíclicos contendo enxofre, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112017015613A2 (pt) gel intestinal de levodopa e carbidopa e métodos de utilização
BR112017015597A2 (pt) moduladores dos receptores da adenosina a3
CO2018000431A2 (es) Compuesto de imidazodiazepina
BR112016026422A2 (pt) solução farmacêutica compreendendo dopamina para uso no tratamento da doença de parkinson

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/04/2014, OBSERVADAS AS CONDICOES LEGAIS